Retinal synthesis of melatonin, a potent modulator of rhythmic retinal processes, is elevated at night as a result of regulation by a circadian clock. Despite high nocturnal
synthetic capacity, both melatonin content and release are low in the retina of the frog Xenopus laevis. We report here that cultured eyecups from Xenopus have the capacity for rapid metabolic breakdown of melatonin. Pharmacological analysis indicates that the initial step in this degradation pathway is deacetylation of melatonin by the enzyme aryl acylamidase (aryl-acylamide amidohydrolase, EC 3.5.1.13). This produces 5-methoxytryptamine, which is then deaminated by monoamine oxidase [amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4], producing 5-methoxyindoleacetic acid and 5-methoxytryptophol. Inhibition of aryl acylamidase with eserine dramatically increases the release of endogenous melatonin by eyecups cultured at night, indicating that this pathway is the normal fate of retinal melatonin. Metabolism within the eye suggests a local neuromodulatory role for retinal melatonin, in contrast to the hormonal role of pineal melatonin.
Melatonin (N-acetyl-5-methoxytryptamine) appears to play a major role in circadian regulation of retinal physiology (1) . It mimics darkness in its effects on rod photoreceptor disc shedding (2) , cone myoid length (3) , movement of pigment granules in the pigment epithelium (4) (5) (6) , and retinal dopamine release (7) . Melatonin synthesis in the retina, as in the pineal gland, is elevated at night as a result of regulation by light and a circadian oscillator (1, (8) (9) (10) (11) (12) (13) . Melatonin may therefore be a circadian signal for night in the retina.
Pineal melatonin content and release into the circulation appear to reflect directly its synthesis (8, 9) . However, evidence from several species suggests that other unidentified mechanism(s) may be involved in the regulation ofretinal melatonin (14, 15) . For example, in chicken retina, the activity of serotonin N-acetyltransferase, the penultimate enzyme in the synthesis of melatonin, and melatonin content are both high at night, but very little retinal melatonin enters the bloodstream (14) . Despite high nocturnal serotonin Nacetyltransferase activity in the retina of Xenopus (12, 13), we found in preliminary experiments that retinal melatonin content and release of melatonin by cultured eyecups were both surprisingly low (<10 pg per retina and <10 pg/hr, respectively). One possible explanation for these results is that retinal melatonin is degraded within the eye. We have used a cultured Xenopus eyecup preparation to examine this possibility.
MATERIALS AND METHODS
Eyecup Culture. Postmetamorphic juvenile Xenopus laevis were maintained in a cycle of 12 hr light/12 hr dark for at least 4 weeks before use in experiments. Eyecups, including the retina, pigment epithelium, choroid, and sclera, were prepared and cultured individually in 1 ml of defined culture medium as described (16 (20) . The curves were parallel, with slopes of -0.914 + 0.028 and -0.927 + 0.067, respectively. Melatonin (2.5, 5, 10, 25, 50, and 100 pg) added to samples of culture medium from eserine-treated day and night and control night eyecups was quantitatively recovered in the assay. The slopes of the recovery curves were 1.03, 1.07, and 0.92, respectively.
RESULTS
To determine whether ocular tissue has the capacity for metabolism of melatonin, we cultured Xenopus eyecups in 1098 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
defined medium containing 100 nM [methoxy-3H]melatonin. After a 3-hr incubation, samples of the culture medium and extracts of the combined retina, pigment epithelium, and choroid were separated by reverse-phase HPLC. Analysis of fractions revealed the production of three radioactive metabolites from the added melatonin ( Fig. 1 A-C) . In this experiment, the amount of [3H]melatonin in the medium was reduced 18%, from 687,000 cpm per 100 Al in control medium to 560,000 + 47,500 cpm per 100 A.l (mean + SD; n = 4) during a 3-hr incubation. This reduction was entirely accounted for by the production of the three metabolites. The tissue concentration of [3H]melatonin at the end of this experiment was 0.24 ± 0.084 pmol per mg of protein, and metabolites were produced at an average rate of 16.9 ± 4.9 pmol per hr per mg of protein (means ± SD). Thus, under these conditions, the entire tissue content of [3H]melatonin was turned over in 1 min.
The HPLC retention times of melatonin and its metabolites are reduced slightly by the tritiated methoxy group, prevent-A. Tissue extract were incubated in medium containing 1 puM unlabeled melatonin, and the culture medium was analyzed by HPLC with fluorescence detection. Three fluorescent compounds, similar to the radiolabeled metabolites in relative amounts and chromatographic behavior, were released by the eyecups into the culture medium (Fig. 1D) . These compounds, with retention times of 8.2, 10.9, and 12.1 min under standard chromatographic conditions, were identified as 5-methoxytryptamine, 5-methoxyindoleacetic acid, and 5-methoxytryptophol, respectively. Under several different chromatographic conditions, these compounds were indistinguishable from standards. When eyecups were incubated without added melatonin, 5-methoxyindoleacetic acid was detectable at low levels by HPLC with fluorescence detection in culture medium; endogenous melatonin and the other metabolites were detectable only after extraction and concentration (data not shown).
A pathway that produces these metabolites from melatonin has previously been described as a minor route of melatonin metabolism in the liver (21) . This pathway (Fig. 2) involves deacetylation of melatonin by aryl acylamidase (arylacylamide amidohydrolase, EC 3.5.1.13) to produce 5-methoxytryptamine. Deamination of 5-methoxytryptamine by monoamine oxidase [amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] produces 5-methoxyindoleacetaldehyde, which is further oxidized to 5-methoxyindoleacetic acid or reduced to 5-methoxytryptophol. We used inhibitors of monoamine oxidase and aryl acylamidase to test the hypothesis that this is the pathway for melatonin metabolism in the eye. When pargyline, a monoamine oxidase inhibitor, was added to the culture medium at a concentration of 100 ,uM, the production of 5-methoxyindoleacetic acid and 5-methoxytryptophol from [3H]melatonin was blocked, and 5-methoxytryptamine accumulated in the tissue (Fig. 3A) . This indicates that the initial step in the breakdown of melatonin is deacetylation to 5-methoxytryptamine, which is then deaminated by monoamine oxidase. Values are means ± SEM from four individually cultured eyecups per group; asterisks indicate significant differences from controls as follows: *, P < 0.05; **, P < 0.01; one-tailed t test. ND, not detectable.
Aryl acylamidase, a deacetylase that appears to be related to acetylcholinesterase, can be inhibited by eserine (22) . Eserine (100 AM) inhibited the production of all metabolites from [3H]melatonin and caused increased accumulation of melatonin in the tissue (Fig. 3B) , consistent with a primary role for aryl acylamidase in the ocular metabolism of melatonin. Lower concentrations of eserine (1 and 10 ,uM) were ineffective. To determine whether this metabolism is the normal fate of melatonin synthesized in the retina, we used eserine to block aryl acylamidase in eyecups cultured at different times of day and night in the absence ofadded melatonin. The endogenous melatonin released into the medium by individual eyecups was measured by radioimmunoassay (Fig. 4) . At night, when serotonin N-acetyltransferase activity is high, eyecups treated with eserine released -7 times as much melatonin as controls. In all daytime groups, melatonin levels were near or below the level of accurate quantification by the RIA. Because eserine is expected to increase retinal acetylcholine levels by inhibiting acetylcholinesterase, other eyecups were cultured with carbachol, an agonist of acetylcholine receptors. Carbachol had no effect, indicating that the increased melatonin release was not the result of increased retinal acetylcholine levels. Values are means ± SEM (n = 5) of total radioimmunoassayable melatonin in 1 ml of culture medium after 4-hr incubations. In the presence of eserine, nighttime melatonin release by eyecups is increased with respect to control nighttime samples and to all daytime samples (analysis of variance, Scheffe's test: P < 0.01). In untreated controls, significant melatonin release is detectable only at night. The acetylcholine agonist carbachol has no effect on melatonin release when compared to untreated controls. first step in this breakdown pathway is deacetylation by aryl acylamidase. Several forms of aryl acylamidase have been described that differ in tissue localization, substrate specificity, and sensitivity to inhibitors (22, 23) . The concentration of eserine required to significantly inhibit the metabolism of melatonin (100 ,uM) was relatively high. This may indicate that the ocular aryl acylamidase is one of the forms less sensitive to eserine or that access of the drug to the enzyme was limited in the eyecup.
When eyecups were cultured with eserine at a concentration sufficient to inhibit the deacetylation of melatonin, the release of melatonin into culture medium was increased dramatically, but eserine had no effect during the day. The resulting diurnal variation in melatonin release is similar to that reported for the melatonin synthetic enzyme serotonin N-acetyltransferase in Xenopus retina (12, 13) . These results suggest that retinal melatonin production is elevated at night, but release of melatonin from the eyecup is prevented by local metabolism. A similar mechanism may provide an explanation for the relatively small contribution of retinal melatonin to circulating levels in avian species (14, 15) and the low melatonin content in the retina of mammals (24, 25) .
Ocular metabolism suggests a local role for retinal melatonin. This pathway may be a mechanism for regulation of local concentrations of melatonin, which is a potent modulator of cellular processes in photoreceptors (2, 3) , the retinal pigment epithelium (4-6), and dopaminergic amacrine cells (7) . An alternative function for this pathway may be in the synthesis of other biologically active methoxyindoles. 5-Methoxytryptophol has effects on disc shedding similar to those of melatonin (2), and 5-methoxytryptamine has been shown to affect serotonergic neurotransmission in the central nervous system (26) . Synthesis of these compounds in the retina has been demonstrated previously, but it was assumed that they were made by methylation of serotonin (5-hydroxytryptamine) and deaminated serotonin metabolites through the action of hydroxyindole-O-methyltransferase (27) . Our results show that they can also be synthesized through the degradation of melatonin.
Previous attempts to demonstrate deacetylation of melatonin by aryl acylamidase in the brain and pineal gland have been unsuccessful (21, 23) . In fact, no endogenous substrate has been found for the brain and pineal forms of this enzyme. The majority of circulating melatonin is cleared by conversion to 6-hydroxymelatonin in the liver; only 1-2% is deacetylated by liver aryl acylamidase (21, 28, 29) . Thus, the eye may be unique in its use of this pathway as a major route of melatonin metabolism.
